Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEP) Depreciation & Amortization (CF) (2022 - 2025)

Historic Depreciation & Amortization (CF) for Coeptis Therapeutics Holdings (COEP) over the last 4 years, with Q3 2025 value amounting to $295303.0.

  • Coeptis Therapeutics Holdings' Depreciation & Amortization (CF) rose 1802.16% to $295303.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year increase of 1350.51%. This contributed to the annual value of $1.0 million for FY2024, which is 3.92% down from last year.
  • As of Q3 2025, Coeptis Therapeutics Holdings' Depreciation & Amortization (CF) stood at $295303.0, which was up 1802.16% from $295303.0 recorded in Q2 2025.
  • In the past 5 years, Coeptis Therapeutics Holdings' Depreciation & Amortization (CF) ranged from a high of $295303.0 in Q1 2025 and a low of $250211.0 during Q1 2024
  • For the 4-year period, Coeptis Therapeutics Holdings' Depreciation & Amortization (CF) averaged around $259291.7, with its median value being $250310.0 (2023).
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first decreased by 3.92% in 2024, then skyrocketed by 1802.16% in 2025.
  • Quarter analysis of 4 years shows Coeptis Therapeutics Holdings' Depreciation & Amortization (CF) stood at $250346.0 in 2022, then fell by 0.01% to $250310.0 in 2023, then decreased by 0.04% to $250212.0 in 2024, then rose by 18.02% to $295303.0 in 2025.
  • Its last three reported values are $295303.0 in Q3 2025, $295303.0 for Q2 2025, and $295303.0 during Q1 2025.